Wound Healing:

1. The macrophage-activating lipopeptide-2 accelerates wound healing in diabetic mice.
   Deiters, U, Barsig J, Tawil, B, Muhlradt, PF. Exp. Dermatol. 2004 Dec;13: 731-739.
   
   
2. Fibrin as a delivery vehicle for active macrophage activator lipoprotein-2 peptide: in vitro studies.
   Cole M, Cox S, Inman E, Chan C, Mana M, Helgerson S, Tawil B. Wound Repair Regen. 2007 Jul-Aug;15(4):521-9.
   
   
3. Intracutaneous injection of the macrophage-activating lipopeptide-2 (MALP-2) which accelerates wound healing in mice--a phase I trial in 12 patients.
   Niebuhr M, Mühlradt PF, Wittmann M, Kapp A, Werfel T. Exp Dermatol. 2008 Dec;17(12):1052-6.
   
   
4. Toll-like receptor 2/6 stimulation promotes angiogenesis via GM-CSF as a potential strategy for immune defense and tissue regeneration.
   Grote K, Schuett H, Salguero G, Grothusen C, Jagielska J, Drexler H, Mühlradt PF, Schieffer B. Blood. 2010 Mar 25;115(12):2543-52. Epub 2010 Jan 7.
   
   

Oncology:

1. Intratracheal macrophage-activating lipopeptide-2 reduces metastasis in the rat lung.
   Shingu K, Kruschinski C, Luhrmann A, Grote K, Tschernig T, Von Horsten S, Pabst R. Am J Respir Cell Mol Biol. 2003 Mar;28(3):316-21.
   
   
2. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.
   Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P, Sauerbruch T, Schmidt-Wolf IG, Muhlradt PF, Schmidt J, Marten A. Gut. 2004 Mar;53(3):355-61.
   
   
3. Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.
   Schmidt J, Welsch T, Jäger D, Mühlradt PF, Büchler MW, Märten A. Br J Cancer. 2007 Sep 3;97(5):598-604. Epub 2007 Jul 31.
   
   

Adjuvant:

1. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant.
   Rharbaoui F, Drabner B, Borsutzky S, Winckler U, Morr M, Ensoli B, Muhlradt PF, Guzman CA.
   Eur J Immunol. 2002 Oct;32(10):2857-65.
   
   
2. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
   Borsutzky S, Fiorelli V, Ebensen T, Tripiciano A, Rharbaoui F, Scoglio A, Link C, Nappi F, Morr M, Butto S, Cafaro A, Muhlradt PF, Ensoli B, Guzman CA.
   Eur J Immunol. 2003 Jun;33(6):1548-56.
   
   
3. A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.
   Schulze K, Staib C, Schätzl HM, Ebensen T, Erfle V, Guzman CA. Vaccine. 2008 Dec 2;26(51):6678-84.
   
   
4. Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant.
   Cataldi A, Yevsa T, Vilte DA, Schulze K, Castro-Parodi M, Larzábal M, Ibarra C, Mercado EC, Guzmán CA. Vaccine. 2008 Oct 16;26(44):5662-7. Epub 2008 Sep 21.
   
   

Sepsis/Infection:

1. Toll-like receptor 2- and 6-mediated stimulation by macrophage-activating lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in mice, which results in protection from tumor necrosis factor alpha but in only partial protection from lethal LPS doses.
   Deiters U, Gumenscheimer M, Galanos C, Muhlradt PF.
   Infect Immun. 2003 Aug;71(8):4456-62.
   
   
2. Attenuated pathogenesis of polymicrobial peritonitis in mice after TLR2 agonist pre-treatment involves ST2 up-regulation.
   Feterowski C, Novotny A, Kaiser-Moore S, Muhlradt PF, Rossmann-Bloeck T, Rump M, Holzmann B, Weighardt
   H. Int Immunol. 2005 Aug;17(8):1035-46.
   
   
3. Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia.
   Reppe K, Tschernig T, Lührmann A, van Laak V, Grote K, Zemlin MV, Gutbier B, Müller HC, Kursar M, Schütte H, Rosseau S, Pabst R, Suttorp N, Witzenrath M.Am J Respir Cell Mol Biol. 2009 Apr;40(4):474-81. Epub 2008 Oct 17.
   
   
4. The Toll-like Receptor 2/6 Ligand MALP-2 Reduces the Viability of Mycobacterium tuberculosis in Murine Macrophages.
   Palma C, Iona E, Ebensen T, Guzman CA, Cassone A. Open Microbiol J. 2009 Apr 3;3:47-52.
   
   
5. Synthetic lipopeptide MALP-2 inhibits intracellular growth of Mycobacterium bovis BCG in alveolar macrophages-preliminary data.
   Jörgens G, Bange FC, Mühlradt PF, Pabst R, Maus UA, Tschernig T. Inflammation. 2009 Aug;32(4):247-51.
   
   
6. Macrophage activating lipopeptide-2 (MALP-2) exerts protective effects in a murine sepsis model.
   Zeckey C, Tschernig T, Hildebrand F, Frink M, Frömke C, Dorsch M, Krettek C, Barkhausen T. Shock. 2009 Nov 20. [Epub ahead of print]
   
   
7. Beneficial effects of TLR-2/6 ligation in pulmonary bacterial infection and immunization with Pseudomonas aeruginosa.
   Kerber-Momot T, Leemhuis D, Lührmann A, Munder A, Tümmler B, Pabst R, Tschernig T. Inflammation. 2010 Feb;33(1):58-64.